Genes involved in fatty acid catabolism have undergone extensive duplication in the genus Mycobacterium, which includes the etiologic agents of leprosy and tuberculosis. Here, we show that prokaryotic-and eukaryotic-like isoforms of the glyoxylate cycle enzyme isocitrate lyase (ICL) are jointly required for fatty acid catabolism and virulence in Mycobacterium tuberculosis. Although deletion of icl1 or icl2, the genes that encode ICL1 and ICL2, respectively, had little effect on bacterial growth in macrophages and mice, deletion of both genes resulted in complete impairment of intracellular replication and rapid elimination from the lungs. The feasibility of targeting ICL1 and ICL2 for chemical inhibition was shown using a dual-specific ICL inhibitor, which blocked growth of M. tuberculosis on fatty acids and in macrophages. The absence of ICL orthologs in mammals should facilitate the development of glyoxylate cycle inhibitors as new drugs for the treatment of tuberculosis.
Microorganisms that invade, replicate and persist within mammalian hosts must acquire and assimilate carbon substrates from host tissues. With few exceptions, little is known about the nutrient sources and metabolic pathways used by pathogens during infection 1 . Metabolic adaptations to tissue environments are thought to contribute to the difficulty in eradicating drug-susceptible microbes despite prolonged therapy with appropriate drugs 2 , a phenomenon known as phenotypic drug tolerance 3 . In vivo drug tolerance is a major reason that tuberculosis therapy requires administration of multiple drugs for six months or longer, resulting in high rates of patient nonadherence, treatment failure and acquired drug resistance 4 . Elucidation of the metabolic pathways required for growth and persistence of Mycobacterium tuberculosis in the mammalian lung could point to new avenues of intervention against this recalcitrant pathogen 5 .
Several lines of evidence suggest that pathogenic mycobacteria primarily use fatty acids rather than carbohydrates as carbon substrates during infection. Respiration of M. tuberculosis grown in mouse lungs is strongly stimulated by fatty acids but is unresponsive to carbohydrates 6 . Several glycolytic enzymes are apparently dispensable for growth and persistence of M. tuberculosis in mice 7 , and the terminal step in glycolysis is blocked in the closely related zoonotic pathogen Mycobacterium bovis as a result of a mutation in pykA, which encodes pyruvate kinase 8 . Restricted carbohydrate availability in vivo is further suggested by the recent demonstration that phosphoenolpyruvate carboxykinase (PCK) is essential for virulence in M. bovis 9, 10 ; in the absence of carbon flux through glycolysis, PCK is required for production of the essential biosynthetic precursor phosphoenolpyruvate (PEP) from tricarboxylic acid (TCA) cycle intermediates (Fig. 1a) . These observations are consistent with the hypothesis that pathogenic mycobacteria chiefly subsist on fatty acid substrates during infection.
Two pathways are specifically required for utilization of fatty acids: the catabolic beta-oxidation cycle that degrades fatty acids to acetylCoA (C 2 ) units, and, if glycolytic substrates are absent or sparse, the anaplerotic glyoxylate cycle. Microorganisms rely on the glyoxylate cycle to replenish TCA cycle intermediates during growth on fatty acid substrates, when concentrations of PEP and pyruvate are insufficient to support anaplerosis through conversion to oxaloacetate by PEP carboxylase (PPC) or pyruvate carboxylase (PCA), respectively (Fig. 1a) . The glyoxylate cycle facilitates the biosynthesis of essential cell constituents from C 2 units by generating C 4 intermediates that serve as biosynthetic precursors 11 . In conjunction with PCK or malic enzyme 12 , the glyoxylate cycle can also generate the essential C 3 biosynthetic precursors PEP and pyruvate, respectively (Fig. 1a) . The extensive duplication of genes encoding beta-oxidation enzymes in M. tuberculosis 13, 14 poses an obstacle to genetic analysis of this pathway's role in virulence as a result of potential functional redundancy of paralogous genes. In contrast, the glyoxylate cycle in M. tuberculosis apparently comprises a single gene encoding malate synthase and two genes encoding isocitrate lyases (Fig. 1a) 13, 14 . The smaller isocitrate lyase gene (icl1) encodes an enzyme closely related to isocitrate lyases in other eubacteria; the larger gene (icl2) encodes a protein more homologous to eukaryotic isocitrate lyases (Fig. 1b) . Both recombinant enzymes show isocitrate lyase activity in vitro, although ICL1 is more active than ICL2 (ref. 15 ). Expression of both icl1 (ref. 16 ) and icl2 (E.J.M.-E., unpublished data) is upregulated in M. tuberculosis isolated from mouse lungs as compared to bacteria grown in vitro.
Previously we reported that disruption of icl1 impaired the chronicphase persistence of M. tuberculosis in mice and had little effect on replication during the acute phase of infection 17 ; the role of icl2 was not addressed. Here, we adduce genetic and chemical evidence that icl1 and icl2 are jointly required for growth, survival and virulence of M. tuberculosis in macrophages and mice. Recent studies have suggested that the glyoxylate cycle is involved in the virulence of other bacterial and fungal pathogens [18] [19] [20] [21] [22] ; so, chemical inhibitors of this pathway could have broad therapeutic utility. The development of new drugs targeting the glyoxylate cycle should be facilitated by the apparent absence of this pathway in mammalian cells 23 .
RESULTS

ICL isoenzymes in M. tuberculosis
The predicted gene products of icl1 (428 amino acids) and icl2 (766 amino acids) are 27% identical overall. Bioinformatics analysis showed three distinct groups of ICL proteins (unpublished data E.J.M.-E.), which differed in length and domain organization (Fig. 1b) Group II ICLs included medium-length plant and fungal ICLs, which contained a central domain (Domain II) absent in group I. Group III ICLs, so far identified only in Mycobacterium, had a long C-terminal domain absent in groups I and II; they also contained a central region with considerable homology to the central domain of the eukaryotic ICLs and were overall ∼35% identical to them (Fig. 1b) . In silico modeling of the three-dimensional structure of ICL2, based on the X-ray crystal structures of the group I ICL1 from M. tuberculosis 24 and the group II ICL from Aspergillus nidulans 25 , showed a considerable level of structural concordance (Fig.  1c) . Notably, the active-site loops of ICL1 and ICL2, containing the conserved catalytic motif KKCGH, were nearly superimposable (Fig. 1c) . Thus, despite the limited homology between ICL1 and ICL2, conservation of tertiary structure and enzymatic activity suggested that these enzymes might provide overlapping biological functions.
ICL is required for growth on fatty acid substrates
To assess the role of the glyoxylate cycle in fatty acid metabolism, we constructed strains of M. tuberculosis in which icl1, icl2 or both were deleted. Deletion of icl1 or icl2 alone had little effect on bacterial replication kinetics in media containing glycerol ( Fig. 2a) , glucose ( Fig. 2b) , short-chain fatty acids ( Fig. 2c-e) or long-chain fatty acids ( Fig. 2f-h ) as carbon sources. In contrast, deletion of both icl1 and icl2 eliminated growth on fatty acids but had little effect on use of carbohydrates. A slight but reproducible lag was observed for growth of the ∆icl1 ∆icl2 strain in glucose-containing media (Fig. 2b) , indicating some carbon flux through the glyoxylate cycle under these conditions, as reported in Corynebacterium glutamicum 26 . Complementation of the ∆icl1 ∆icl2 mutant with plasmids carrying icl1or icl2 restored growth on fatty acids ( Fig. 2c-h ), confirming that these genes encode functionally redundant enzymes that are jointly required for fatty acid metabolism.
ICL is required for virulence in mice
We assessed the role of the glyoxylate cycle in replication and persistence of M. tuberculosis in vivo by infecting wild-type C57BL/6 mice with strains lacking icl1, icl2 or both (Fig. 3) . Deletion of icl1 resulted in modest reduction of the bacterial load in the lungs during the chronic phase but not the acute phase of infection ( Fig. 3a) and reduced tissue pathology (Fig. 3g) , as reported 17 , whereas deletion of icl2 had no discernible impact on the kinetics of M. tuberculosis growth and persistence (Fig. 3b) or tissue pathology (Fig. 3g) . In contrast, bacteria lacking both icl1 and icl2 were incapable of growth in mice and were rapidly eliminated from the lungs and spleen (Fig. 3c) , which remained culture-negative (detection limit, one colony-forming unit (CFU) per organ) until the experiment was terminated (two years after infection). Mice infected with the ∆icl1 ∆icl2 mutant did not show any appreciable splenomegaly (Fig. 3e) or lung pathology (Fig. 3g) , and remained healthy until the experiment was terminated, whereas mice infected with wild-type bacteria died between 8 and 9 months after infection. Complementation of the ∆icl1 ∆icl2 mutant with a plasmid containing icl1 restored growth (Fig. 3d) and tissue pathology in the lungs (Fig. 3g) and spleen (data not shown); chronic-phase persistence was largely restored as well (Fig. 3d) . Tuberculosis case fatality rates increase in HIV-coinfected people despite appropriate therapy, suggesting that antimicrobial therapies might be less efficacious in immunodeficient individuals 27 . We asked what effect ICL deficiency would have on growth and survival of M. tuberculosis in immunodeficient hosts by infecting highly susceptible mouse strains lacking interferon (IFN)-γ (Ifng -/-) or tumor necrosis factor (TNF)-α receptor 1 (Tnfrsf1a −/− ) 28 . We found that ∆icl1 ∆icl2 bacteria were incapable of replicating in Ifng −/− mice (Fig. 3f) or Tnfrsf1a −/− mice (data not shown), suggesting that ICL inhibitors might have therapeutic value, even in settings of compromised immunity. Previously we reported that the attenuation of ∆icl1 bacteria in C57BL/6 mice was reversed in Ifng −/− mice, suggesting that the in vivo requirement for ICL might be triggered by IFN-γ-mediated macrophage activation 17 consistent with this idea because growth of the ∆icl1 ∆icl2 bacteria was not restored in Ifng −/− mice, although clearance was somewhat delayed in Ifng −/− mice as compared to wild-type mice (Fig. 3f) .
ICL is required for growth and survival in macrophages
The macrophage has a central and dual role in tuberculosis, serving as both a protective immune cell and as a niche for intravacuolar replication and persistence of M. tuberculosis 29 . Previously we reported that deletion of icl1 impaired survival of M. tuberculosis in IFN-γ-activated murine macrophages but had little effect on survival in nonactivated macrophages 17 . In contrast, survival of ∆icl1 ∆icl2 bacteria was impaired in both nonactivated (Fig. 4a) and IFN-γ-activated (Fig. 4b) murine macrophages, although killing was more rapid in the latter. Complementation of the ∆icl1 ∆icl2 strain with plasmids containing icl1 (Fig. 4c,d) or icl2 (Fig. 4e,f) restored replication in nonactivated macrophages (Fig. 4c,e) and survival in IFN-γ-activated macrophages (Fig. 4d,f) . We obtained similar results in assays with human blood monocyte-derived macrophages (Fig. 4g,h) , suggesting that M. tuberculosis might also use the glyoxylate cycle during human infection.
Chemical inhibition of ICL mimics ICL deficiency
Our demonstration that ICL activity is essential for replication and survival of M. tuberculosis in vivo suggested that chemical inhibition of ICL1 and ICL2 might be an effective therapeutic strategy. We therefore tested the ability of the prototype ICL inhibitor 3-nitropropionate (3-NP) 15, 23, 24 to block growth of M. tuberculosis in media containing specific carbon substrates (Fig. 5 ) and in macrophages (Fig. 6) . Growth of M. tuberculosis on glycerol (Fig. 5a) was not affected by the addition of 0.1 mM 3-NP, and growth on glucose (Fig. 5b) was only slightly affected, comparable to the slightly reduced growth kinetics of ∆icl1 ∆icl2 bacteria. In contrast, growth of M. tuberculosis on fatty acids (Fig. 5c,d ) was eliminated by addition of 3-NP, comparable to the phenotype of ∆icl1 ∆icl2 bacteria. Consistent with our interpretation that 3-NP-mediated growth inhibition resulted from inhibition of ICL per se, bacteria that overexpressed ICL1 (sixfold) from a plasmid (Fig. 5f) were less sensitive to 3-NP as compared to wild-type bacteria (Fig. 5e) . (Fig. 6a-d) completely eliminated intracellular growth (Fig. 6b) , comparable to the growth inhibition resulting from deletion of icl1 and icl2 (Fig. 6a) . 3-NP-mediated inhibition of bacterial growth in mouse macrophages was dose dependent (Fig. 6d) , and bacteria that overexpressed ICL1 (sixfold) from a plasmid were more resistant to growth inhibition by 3-NP as compared to wild-type bacteria (Fig. 6c) . We did not perform studies in M. tuberculosis-infected mice because of the known neurotoxicity of 3-NP in mice 30 . Although slightly less effective in human as compared to murine macrophages, 3-NP also inhibited growth of M. tuberculosis in human macrophages in a dosedependent manner (Fig. 6e) . These results provide a proof of concept for the development of ICL inhibitors as antituberculosis drugs.
Addition of 3-NP to M. tuberculosis-infected murine macrophages
DISCUSSION
Carbohydrates are thought to comprise the principal carbon source for pathogenic bacteria in such diverse niches as the intestinal lumen 31 , the host cell cytosol 32 and phagocyte vacuoles 33 . In contrast, pathogenic mycobacteria isolated from the lungs of mice preferentially respire fatty acids rather than carbohydrates 6 , and genes encoding proteins involved in mycobacterial fatty acid metabolism are upregulated in macrophages 34 and mice 16 . A central role for fatty acid metabolism is further suggested by the extensive duplication of genes involved in lipid degradation in M. tuberculosis 13, 14 . Homologous gene pairs include icl1 and icl2, which encode isocitrate lyases of the glyoxylate cycle (Fig. 1a) . Previously, we reported that icl1 is dispensable for acute-phase growth but essential for chronic-phase persistence in M. tuberculosis-infected mice, and we proposed that M. tuberculosis might switch to fatty acid catabolism at the transition from the acute to the chronic phase of infection 17 . Here, we adduce evidence that icl1 and icl2 are jointly required for survival of M. tuberculosis in macrophages and mice at early as well as late stages of infection, indicating that fatty acid catabolism has a more fundamental role during infection than we had previously thought. In the future, the roles of ICL1 and ICL2 in chronic-phase persistence could be addressed using new technologies for conditional gene expression in mycobacteria 35, 36 . Our studies raise the possibility that drugs capable of inhibiting both ICL isoforms might have potent antimycobacterial activity. But there are significant differences in tuberculosis pathology in mice and humans, and it is possible that the in vivo metabolism of M. tuberculosis might be influenced by these factors. Resolution of these issues will require studies on the role of the glyoxylate cycle in human disease. Primacy of fatty acid metabolism and essentiality of the glyoxylate cycle do not rule out the possibility that M. tuberculosis might also have access to carbohydrates in vivo. During growth on all types of carbon substrates, bacteria must replenish intermediates of central metabolism that are siphoned off to biosynthetic pathways. Nutrient availability and growth rate determine which anaplerotic pathways are used. Escherichia coli uses PPC to synthesize oxaloacetate during rapid growth with excess glucose, but switches to the glyoxylate cycle during slow growth with limiting glucose 37 . Similarly, Corynebacterium glutamicum uses PPC or PCA to replenish oxaloacetate during growth on glucose 38 (Fig. 1a) , but switches to the glyoxylate cycle when growing on mixtures of glucose and fatty acids 26 .
Adaptation of M. tuberculosis to low concentrations of glycolytic substrates in vivo could involve reduced flux of carbon through glycolysis in order to conserve glycolytic intermediates for essential biosynthetic processes. This idea is consistent with preliminary evidence that glucokinase and a putative carbohydrate transporter are essential for growth of M. tuberculosis in mice, whereas the glycolytic steps catalyzed by triosephosphate isomerase, glyceraldehyde 3-phosphate dehydrogenase and phosphoglycerate kinase are apparently dispensable 7 . If correct, these observations suggest that during infection, glycolysis is not the source of PEP, an essential biosynthetic precursor of aromatic amino acids and peptidoglycan. Instead, PEP could be generated by the sequential action of the glyoxylate cycle, which converts acetyl-CoA to oxaloacetate, and PCK, which decarboxylates oxaloacetate to PEP (Fig. 1a) . Consistent with this idea, pckA (which encodes PCK) is upregulated in the lungs of M. tuberculosis-infected mice 16 and is essential for virulence in M. bovis 9, 10 .
During infection, M. tuberculosis could obtain fatty acids from the host cell by hydrolysis of cell membrane lipids 39 ; consistent with this possibility, M. tuberculosis genes encoding exported phospholipases are jointly required for growth in the lungs of mice 40 . M. tuberculosis might also catabolize internal lipid reserves such as triacylglycerol, particularly during persistence 41 . Beta-oxidation of odd-chain fatty acids generates both acetyl-CoA (C 2 ) and propionyl-CoA (C 3 ); the latter can be metabolized through the methylcitrate cycle (Fig. 1a) , which is required for propionate catabolism in fungi and eubacteria 42, 43 . The M. tuberculosis genome encodes homologs of methylcitrate synthase (prpC) and methylcitrate dehydratase (prpD), which are upregulated during infection of macrophages 34 . Methylisocitrate lyase (prpB) is apparently missing in M. tuberculosis; however, ICLs show limited homology to methylisocitrate lyases and possess weak methylisocitrate lysase activity 44 . These observations, and our finding that ICL1 and ICL2 are jointly required for growth of M. tuberculosis on p ropionate (Figs. 2d and 5c) , raise the possibility that these enzymes might substitute for PRPB in the methylcitrate cycle.
Our studies show that the glyoxylate cycle is essential for M. tuberculosis growth and persistence in macrophages and mice. We have presented structural and biological evidence indicating the feasibility of developing dual-specificity ICL1 and ICL2 inhibitors as potential therapeutic agents for tuberculosis. Mutations in icl1 and icl2 could also be incorporated in the design of live attenuated vaccines that might be safe for use in immunosuppressed subjects, such as people with HIV/AIDS. As a new target for drug development, the glyoxylate cycle is attractive because it is apparently absent in mammalian cells 23 and is essential for virulence in other major pathogens, such as Candida albicans 19 . There is an urgent need for new and better drugs to treat persistent infections like candidiasis and tuberculosis, which require lengthy treatment regimens with potentially toxic drugs, resulting in patient nonadherence, treatment failure and drug resistance. Bacteriologic media. We stored M. tuberculosis (Erdman) at -80 °C in 15% glycerol. We grew bacteria at 37 °C in Middlebrook 7H9 broth (DifCo) with 0.5% albumin, 0.085% NaCl, 0.05% Tween-80, 0.5% glycerol and 0.2% glucose, or on Middlebrook 7H10 agar (DifCo) with 10% OADC (DifCo) and 0.5% glycerol. For carbon-use experiments, we grew bacteria in 7H9 with 0.5% albumin, 0.085% NaCl, 0.05% Tween-80 and carbon substrate at 0.1% (wt/vol). We purchased hygromycin (50 µg/ml), kanamycin (25 µg/ml), streptomycin (20 µg/ml) and 3-NP from Sigma. We measured oxidation of 14 C-palmitate to 14 C-CO 2 using BACTEC (Becton Dickenson).
Strain construction.
We subcloned a genomic KpnI fragment containing icl2 into pBSKS -(Stratagene) and replaced an internal 1.8 kbp MscI fragment with an aph kanamycin resistance (Km r ) cassette (pUC4 1.3 kbp BamHI fragment) to generate pEM028. We cloned the KpnI fragment containing ∆icl2:aph into the SalI site of pEM025, a shuttle vector containing the pAL5000 ori 45 , aadA streptomycin-resistance (Sm r ) marker (pHP45 1.9 kb DraI fragment 46 ) and sacB counterselection marker to generate pEM029-1. We recombined the ∆icl2:aph allele into the M. tuberculosis chromosome by selection of Km r transformants and counterselection on 5% sucrose 47 . We generated the ∆icl1 ∆icl2 mutant by disrupting icl2 in the chromosome of ∆icl1 bacteria 17 . We confirmed replacement of wild-type icl2 with ∆icl2:aph by PCR and Southern blot. We constructed pEM263-4 (pICL1) by subcloning a 1.6 kb SpeI fragment containing icl1 into the HpaI site of pEM262, an episomal vector derived from pMV261 (ref. 48 ) by replacing the Km r cassette with the Sm r cassette. We constructed pEM3E4-8 (pICL2) by inserting a 6.1 kbp KpnI fragment containing icl2 into the HpaI site of pEM262.
Mouse macrophage infections.
We flushed bone marrow from mouse femurs and incubated (37°C, 5% CO 2 ) it for 7 d in DMEM (Cellgro) with 0.58 g/L L-glutamine, 1 mM sodium pyruvate, 10% heat-inactivated FBS (Hyclone), 10 mM Hepes pH 7.55, 100 U/ml penicillin G, 100 µg/ml streptomycin and 20% L929 cell-conditioned medium. We released adherent cells with 1 mM EDTA-PBS, seeded them in 12-well plates (2 × 10 5 cells/well) and incubated them for 24 h before infection. Where indicated, we added 50 U/ml recombinant IFN-γ (R&D Systems) 16 h before infection and thereafter. We grew bacteria to optical density at 600nm (OD 600 ) 0.5 in 7H9, washed them in PBS with 0.05% Tween-80 (PBST) and centrifuged them for 5 min at 130g to remove aggregates. We infected macrophage monolayers (multiplicity of infection (MOI), 2:1) in DMEM with 0.58 g/L L-glutamine, 1 mM sodium pyruvate, 5% heat-inactivated FBS and 5% heat-inactivated horse serum (Gibco). After 4 h, we washed monolayers to remove nonadherent bacteria and incubated them with medium changes every 36 h (heat-inactivated horse serum omitted).
Where indicated, we added 3-NP 4 h after infection and onward. 3-NP had no effect on macrophage adherence or viability. We washed infected monolayers and lysed them with 0.5% Triton X-100. We plated lysates on 7H10 and enumerated bacterial CFU after 3-4 weeks at 37 °C.
Human macrophage infections.
We isolated mononuclear cells from whole human blood (New York Blood Center) on Ficoll-plaque gradients (Pharmacia Biotech). We seeded cells in 12-well plates (2.4 × 10 6 cells/well) and incubated them (37 °C, 5% CO 2 ) in HIPHS-RPMI (which is RPMI-1640 (Life Technologies) with 10% heat-inactivated pooled human serum (Labquib, Ltd.)), 10 mM Hepes at pH 7.55 and 20 µg/ml gentamicin. After 2 h, we washed monolayers to remove nonadherent cells and incubated them for 7 d. We washed macrophage monolayers (2 × 10 5 cells/well) with RPMI and infected them with M. tuberculosis per the procedures used to infect mouse macrophages, except that cells were cultured in HIPHS-RPMI (gentamicin omitted).
Mouse infections.
We purchased male and female C57BL/6, Ifng −/− and Tnfrsf1a −/− mice (5-8 weeks old) from Jackson Laboratory. We grew bacteria to OD 600 0.5 in 7H9, collected them by centrifugation, washed them with PBST, adjusted them to 10 7 CFU/ml and cup-sonicated them to disrupt aggregates. We infected mice by injection of 0.1 ml (10 6 CFU) of the bacterial suspension into a lateral tail vein. Infected mice were killed by CO 2 overdose. We plated lung and spleen homogenates on 7H10 and enumerated bacterial CFU after 3-4 weeks at 37 °C. Tissues were fixed in phosphate-buffered formalin (10%) and stained with hematoxylin and eosin for histopathology. Procedures involving vertebrate animals were reviewed and approved by Rockefeller University's Animal Care and Use Committee.
Statistics. Bacterial CFU plots were compared using Student's two-tailed t-test. 
